A novel NMDAR antagonist provides rapid and sustained antidepressant effects in patients with major depression ― without the dissociative effects common with ketamine, a new phase 2a study suggests.
In the largest study of its kind to date, researchers find the genetic underpinnings of suicide attempts are partially shared and partially distinct from those of related psychiatric disorders.